Cybin is trading 5.9% down at $10.38, with no company-specific announcement or reliable report identified for October 13, 2026, to explain the decline. - The biotech sector was weaker, with XBI down 2.01% during the regular session; sector pressure is plausible context, but no direct cause is established. - The latest identified company news was an October 8 notice about an October 21 investor presentation.